Physician profile
Suzanne Albert
NPI 1104994607
$4,601.95
in general payments reported to CMS, 2019-2025
29 companies · $863 in 2025
The $863 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $571 · 2022: $668 · 2023: $905 · 2024: $1,595 · 2025: $863.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,350 · Education: $13.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,350.35 |
| Education | $13.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,277.36 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Exeltis, USA INC. | $436.76 | 2022-2024 | Slynd, Nuvessa |
| Sumitomo Pharma America, INC. | $430.22 | 2024-2025 | Gemtesa, Myfembree |
| Abbvie INC. | $415.02 | 2021-2024 | |
| Biogen, INC. | $261.20 | 2024-2025 | Zurzuvae |
| Mayne Pharma Commercial LLC | $221.49 | 2024-2025 | |
| Astellas Pharma US INC | $203.18 | 2023-2024 | Veozah |
| Evofem Biosciences, INC. | $178.06 | 2021-2025 | Phexxi, Solosec, Phexx |
| Shield Therapeutics INC | $145.24 | 2023-2025 | Accrufer |
| Abiomed | $137.48 | 2025 | |
| Daiichi Sankyo INC. | $134.23 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $110.65 | 2023 | Spravato |
| Axonics, INC. | $79.51 | 2023 | Axonics |
| Coloplast Corp | $75.30 | 2023-2024 | Altis |
| Therapeuticsmd, INC. | $63.54 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $54.21 | 2022-2024 | Novasure, Aptima |
| Lilly USA, LLC | $53.47 | 2024 | Zepbound |
| Ibsa Pharma INC. | $46.81 | 2021-2025 | Licart, Tirosint, Flector |
| Exact Sciences Corporation | $45.37 | 2023-2025 | Cologuard Collection Kit |
| Agile Therapeutics, INC. | $44.42 | 2021-2022 | |
| Glaxosmithkline, LLC. | $31.67 | 2025 | Shingrix |
| Organon LLC | $31.38 | 2024 | |
| Currax Pharmaceuticals LLC | $25.16 | 2022 | |
| Dysis Medical, INC. | $19.70 | 2021 | |
| Coopersurgical, INC. | $19.67 | 2025 | Paragard T 380a |
| Avion Pharmaceuticals | $17.04 | 2022 | |
| Amgen INC. | $17.01 | 2021 | |
| Bausch Health US, LLC | $13.45 | 2022 | |
| Millicent US INC | $13.35 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suzanne Albert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.